anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: Back pain is one of the most challenging health conditions to manage. Healthcare providers face additional challenges when managing back pain for patients with culturally diverse backgrounds including addressing linguistic barriers and understanding patients' cultural beliefs about pain and healthcare. Knowledge about patients with culturally diverse backgrounds experiencing back pain and the interventions available to them is limited. Therefore, this study aims to describe the characteristics of patients with culturally diverse backgrounds experiencing back pain and the video interpretation intervention offered to them and further to explore the clinician's perspective on this intervention.
METHODS: Data were collected from the electronic medical records and the Interpreter Gateway. Four clinicians participated in a group interview, where they described and evaluated the video interpretation intervention in detail inspired by the template for intervention description and replication (TIDieR) checklist and guide.
RESULTS: A total of 119 (68%) patients accepted the intervention (53% women, mean 44 years). These patients represent 24 different languages, with 50% having at least one hospital-registered diagnosis and a mean number of five outpatient contacts, 1 year before receiving the intervention. Fifty-seven patients did not accept the intervention and declined interpretation or opted to use relatives or through video conferencing equipment. The intervention was positively evaluated by the clinicians.
CONCLUSIONS: The detailed description of the population and the intervention together with the clinician perspective provides a valuable foundation for developing and refining similar interventions, allocating resources, and designing future research studies. The intervention consisted of a consultation lasting up to 2 h delivered by a rheumatologist and a physiotherapist, with a remote interpreter connected.
Amide-thiolate ligands having improved metal chelate formation kinetics are disclosed. The ligands include an amine to facilitate rapid formation of an amine-amide-thiolate intermediate complex, followed by transfer of the metal to or conversion of the ligand to a thermodynamically stable amide-thiolate complex. In one embodiment of the invention, the amine is a tertiary amine, or its equivalent, strategically located to facilitate complex formation. In another embodiment of the invention, the amine is part of pyridine containing a lower alkoxy substituent in the 2 or 4 ring position. O-dealkylation occurs upon complexation causing the amine to become a vinylogous amide as part of a thermodynamically stable amide-thiolate complex. The amide-thiolate ligands of the present invention may be used for post formed labeling of biological substances for use in the fields of diagnosis and therapy.
The invention relates to an ulipristal acetate medicine composition comprising, by weight, 3-10% of ulipristal acetate micro-particles, 70-90% of a diluting agent, 3-6% of a bionding agent, 4-12% of a disintegrant, and 0-2% of a lubricating agent. The particle size D90 of the micro-particles is no higher than 10mum. The diluting agent is selected from lactose, microcrystalline cellulose, mannitol, and mixtures thereof. The bonding agent is hydroxypropyl methylcellulose. The disintegrant is sodium carboxymethyl starch. The lubricating agent is selected from magnesium stearate, silicon dioxide, talc powder, and mixtures thereof. The composition has excellent dissolution profile, good friability, and good homogeneity.
Several studies have shown that diet can modulate the gut microbiome and affect the biology of the immune system. The role of the high-fermented food diet and high-fiber supplementation on gut microbiome in patients with cancer treated with immunotherapy will be evaluated. Fermented diet and high-fiber supplementation rational: a high-fermented food diet promotes gut microbiome composition and lowers systemic inflammatory markers. Additionally, high fiber diet may be associated with improved clinical outcomes in immune checkpoint inhibitor treated cancer patients. The effect of high-fermented food and high-fiber supplementation on gut microbiome and systemic inflammation in patients with cancer will be examined. The results of this study will be used to help to design future dietary intervention trials in cancer patients receiving immunotherapy. Baseline diet information, stool and blood samples will be collected. Patients initially receive high-fermented food diet for 4 weeks, followed by 2-week break/observation period and then cross over to high-fiber supplementation for another 4 weeks, followed by 2 weeks break/observation period. During break/observation period patients can eat any type of food, without dietary restrictions. During the dietary intervention period 24-hour dietary recall information will be collected, stool samples weekly and blood sample every 2-4 weeks.
Chronic kidney disease (CKD) is characterized by a gradual decrease in the glomerular filtration rate (GFR) and proteinuria. CKD is a global health problem, and its incidence has been increasing. The estimated global prevalence of CKD is 8-14%. When kidney function deteriorates gradually, many metabolites accumulate in the body. These accumulated substances, termed as uremic toxins (UTs), can result in adverse pathophysiological outcomes. UTs can affect multiple organs and cause renal fibrosis, vascular calcification, anemia, peripheral arterial disease, adynamic bone disease, adipocyte dysfunction with insulin resistance, impaired immune system, and uremic pruritus.

The pathophysiological mechanisms through which UTs cause multiple organ damage are complex and not completely understood. These mechanisms may include inflammation, reactive oxidative stress, cellular transdifferentiation, impaired mitochondria function, intestinal barrier destruction, and changes in intestinal microbiota.
PURPOSE:The titled film, prepared by adding a specific amount of polypeptide to gelatin, having improved solubility and such improved adhesive property as not to leak the contents therein, e.g. a drug. CONSTITUTION:A soft capsule film prepared by adding 0.5-10wt%, preferably 1.5-6wt%, based on gelatin, polypeptide, having <=10,000, preferably 500-5,000, more preferably 1,000-2,000, molecular weight to the gelatin. The resultant soft capsule film will not deteriorate the solubility thereof even in storing for a long term and is capable of retaining the good adhesive property of the film. Another well-known component, e.g. glycerol, sorbitol, ethylparaben or propylparaben, may be added thereto in addition to the above-mentioned components.
The contribution of environmental, occupational and genetic factors to lymphoma has generated a series of novel findings in studies of Caucasians. However, none of the chemical associations have been conclusively established and the identification of the key, functional alleles in gene regions associated with risk of NHL requires further elucidation. Further, the ability to follow-up, confirm, and extend these observations is limited by the low prevalence and limited range of several important chemical exposures and the high to complete linkage disequilibrium among key candidate genetic loci in Western populations. To optimize the ability to build on and clarify these findings, it is necessary to investigate populations that differ from Caucasians in both exposure patterns and underlying genetic structure. A multidisciplinary case-control study of lymphoma in Asia provides an opportunity to replicate and extend recent and novel observations made in studies among Caucasians in a population that is distinctly different with regard to patterns of key risk factors, including range of exposures, prevalence of exposures, correlations between exposures, and variation in gene regions of particular interest. Thus, a hospital-based case-control study of lymphoma in Eastern Asia (i.e., AsiaLymph) of 4,200 cases and 4,200 controls to be enrolled over a three-year period will be conducted. In addition, 2,000 cases of myeloid leukemias and an additional 2,400 cases with less common lymphoma subtypes will be enrolled as well. The major postulated risk factors for evaluation in this study are chemical exposures (i.e., organochlorines, trichloroethylene, and benzene) and genetic susceptibility. Other factors potentially related to NHL, such as viral infections, UV exposure, medical conditions, and other lifestyle factors will also be explored. A particularly noteworthy aspect of AsiaLymph is central pathology review with immunophenotyping by two of the world s leading lymphoma pathologists, which will enable accurate analysis of findings by molecular and histologic subtypes. AsiaLymph represents the optimal next step in the DCEG lymphoma portfolio. AsiaLymph should confirm and extend previous findings, and yield novel insights into the causes of lymphoma and leukemia in both Asia and the West.
Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK4427296, as IV infusion after completing lymphodepleting chemotherapy.
The investigators are studying an alternate dosing regimen of an approved drug (9vHPV vaccine) in the population for which it is approved. The vaccine is approved for individuals ages 9-45 years old and participants in this study will be 27-45 years of age. The purpose of the study is to examine the immune response of 2 doses of 9vHPV vaccine. The current recommendation is to administer the vaccine in 3 doses (administered at 0, 1-2 months and 6 months) to those 15-45 years of age, but only 2 doses (administered at 0 and 6 months) if the vaccine series is initiated before age 15. The investigators will conduct a randomized study to determine if 2 doses of elicit a similar immune response to that of a standard 3 dose series in individuals 27-45 years of age. Participants in the study group will receive 2 doses of at 0 and 6 months. Participants in the control group will receive 3 doses of 9vHPV vaccine at 0, 2 months, and 6 months. All participants (target accrual n=618) will have 5 mLs of blood drawn at 0, 1, 7, and 12 months. Following the 12-month blood draw, participants randomized to 2-doses will be offered the 3rd dose. Potential participants will be recruited through the University of Texas Medical Branch (UTMB) clinics and surrounding community, and will be screened for inclusion/exclusion criteria. Eligible patients will sign an informed written consent. At their baseline visit, participants will have their blood drawn, be randomized into either the study or control group, and receive their first dose of the HPV vaccine. All participants will receive compensation administered through a ClinCard following each of the 4 blood draws.
AIMS: Mechanical impingement of the iliopsoas (IP) tendon accounts for 2% to 6% of persistent postoperative pain after total hip arthroplasty (THA). The most common initiator is anterior acetabular component protrusion, where the anterior margin is not covered by anterior acetabular wall. A CT scan can be used to identify and measure this overhang; however, no threshold exists for determining symptomatic anterior IP impingement due to overhang. A case-control study was conducted in which CT scan measurements were used to define a threshold that differentiates patients with IP impingement from asymptomatic patients after THA.
METHODS: We analyzed the CT scans of 622 patients (758 THAs) between May 2011 and May 2020. From this population, we identified 136 patients with symptoms suggestive of IP impingement. Among them, six were subsequently excluded: three because the diagnosis was refuted intraoperatively, and three because they had another obvious cause of impingement, leaving 130 hips (130 patients) in the study (impingement) group. They were matched to a control group of 138 asymptomatic hips (138 patients) after THA. The anterior acetabular component overhang was measured on an axial CT slice based on anatomical landmarks (orthogonal to the pelvic axis).
RESULTS: The impingement group had a median overhang of 8 mm (interquartile range (IQR) 5 to 11) versus 0 mm (IQR 0 to 4) for the control group (p < 0.001). Using receiver operating characteristic curves, an overhang threshold of 4 mm was best correlated with a diagnosis of impingement (sensitivity 79%, specificity 85%; positive predictive value 75%, negative predictive value 85%).
CONCLUSION: Pain after THA related to IP impingement can be reasonably linked to acetabular overhang if it exceeds 4 mm on a CT scan. Below this threshold, it seems logical to look for another cause of IP irritation or another reason for the pain after THA before concluding that impingement is present.
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder. Typically, patients will present with tense bullae and intense generalized pruritus with a skin biopsy demonstrating subepidermal split with eosinophils and a direct immunofluorescence highlighting autoantibodies against the basement membrane zone. Prognosis varies, and treatment involves an assessment of the severity of disease to determine whether to initiate topical or systemic immunosuppressive agents. We present an atypical presentation of BP that presented as a 3-to-4-week duration of pruritic small vesicular lesions in the upper chest, scabbed circular lesions along the upper extremity and pinnas of bilateral ear. Initially thought to be herpes zoster infection initially treated with valacyclovir for a week following a prior concern of a concomitant superficial skin infection with cephalexin and prednisone. With no clinical improvement, tissue biopsy was performed that confirmed bullous pemphigoid and treatment with steroid taper, doxycycline, and triamcinolone acetonide 0.1% cream was started. The aim of this case report is to present an atypical presentation of BP and to highlight maintaining a high index of suspicion of BP in patients presenting with disseminated significantly pruritic lesions.
Mycobacterium tuberculosis (Mtb) infects lung myeloid cells, but the specific Mtb-permissive cells and host mechanisms supporting Mtb persistence during chronic infection are incompletely characterized. We report that after the development of T cell responses, CD11clo monocyte-derived cells harbor more live Mtb than alveolar macrophages (AM), neutrophils, and CD11chi monocyte-derived cells. Transcriptomic and functional studies revealed that the lysosome pathway is underexpressed in this highly permissive subset, characterized by less lysosome content, acidification, and proteolytic activity than AM, along with less nuclear TFEB, a regulator of lysosome biogenesis. Mtb infection does not drive lysosome deficiency in CD11clo monocyte-derived cells but promotes recruitment of monocytes that develop into permissive lung cells, mediated by the Mtb ESX-1 secretion system. The c-Abl tyrosine kinase inhibitor nilotinib activates TFEB and enhances lysosome functions of macrophages in vitro and in vivo, improving control of Mtb infection. Our results suggest that Mtb exploits lysosome-poor lung cells for persistence and targeting lysosome biogenesis is a potential host-directed therapy for tuberculosis.
Patients randomized to observation will be observed during the post-operative period for spontaneous Baerveldt-350 tube opening. The ripcord will not be removed unless deemed medically necessary by the study physician.
A system and method to provide a care-based activity recommendation engine are described. The system comprises electronic storage and physical computer processors. The electronic storage stores care recipient profile information for the care recipient including information related to care needs of the care recipient and caregiver profile information including schedule information, resource information, relationship information, or location information for individual caregivers. The processor(s) are in operative communication with the electronic storage and are configured to obtain activity tasks about the care recipient. The processor(s) determine likelihood metric values for the individual caregivers for given activity tasks indicating capacity and/or likelihood of a given caregiver to perform a given activity task. The processor(s) communicate the individual activity task to the individual caregiver responsive to the likelihood metric values indicating that the individual caregiver has the capacity and/or likelihood to complete the individual activity task.
Participants will receive a 1 mg/kg dose of intravenous ketamine 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr ketamine with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure).
The Quadrantectomy Group sample performed adjuvant radiotherapy with a linear accelerator, whose the total dosage was 5000 centigray (cGy), the daily dose 200 cGy distributed into twenty-five sessions, totaling 25 days of treatment. And data from Maximal Respiratory Pressures (MIP/MEP) were collected at two phases in the sample of Quadrantectomy Group: before the first session of radiotherapy and after the twenty-fifth session corresponding to the last day of the radiotherapy treatment.
The invention relates to the field of health products, in particular to a brain boosting oral liquid, which comprises walnut oil, purified water, hawthorn and compound amino acid powder. The brain boosting oral liquid is characterized in that the walnut oil accounts for 15-20 percent of the total weight, the compound amino acid accounts for 20-25 percent of the total weight, the hawthorn accounts for 10-15 percent of the total weight, and the purified water accounts for 40-55 percent of the total weight. A small amount of essence can be added so as to make the taste mellower. A small amount of pigment can be added so as to stimulate appetite. Moreover, Chinese wolfberry extracting liquid can be added so as to further improve the health care effect. The invention has the advantages of nutrition enrichment, fatigue resistance, capability of significantly improving the immunity of the organism, good health care effect and the like.
The present invention provides a new class of compounds presenting a high compatibility with tissues and organic fluids. Such new compounds are polysaccharides essentially formed of units of uronic acid and/or hexosamine, containing nitro groups —ONO 2  covalently bonded to the saccharide structure. Preferably, the polysaccharides according to the invention are prevalently formed of disaccharide repeating units formed of uronic acid and hexosamine. These compounds, in psychological conditions, selectively release NO, allowing a reduction in the amount of NO needed to achieve a determined therapeutical effect. This result has been achieved by functionalizing polysaccharides essentially formed of units of uronic acid and/or hexosamine, with subsituents containing a ONO 2 ? group.
The Neural Communication System consists of two Neuroport Multi-Port Arrays, which are descried in detail in the intervention description. One Neuroport Multi-Port Array is inserted into the posterior parietal cortex, an area of the brain used in reach planning. The second Neuroport Multi-Port Array is inserted into the motor cortex, which is primarily responsible for controlling movement. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to use thought to control a simple computer environment or a tablet computer.
The method for producing ceramic dental prosthesis (10), which includes a frame (12) with a supporting profile and a veneer (14) with a snap profile, comprises fabricating the frames on the basis of the supporting profile and predetermined outer dimension made of first ceramic, overpressing the frame with second ceramic that is different from the first ceramic, determining the position of the supporting profile in overpressed ceramic block (24) and calculating the position of the snap profile in the ceramic block, and subtractively working out the veneer from the overpressed ceramic block. The method for producing ceramic dental prosthesis (10), which includes a frame (12) with a supporting profile and a veneer (14) with a snap profile, comprises fabricating the frames on the basis of the supporting profile and predetermined outer dimension made of a first ceramic, overpressing the frame with a second ceramic, which is different from the first ceramic, determining the position of the supporting profile in the overpressed ceramic block (24) and calculating the position of the snap profile in the ceramic block, subtractively working out the veneer from the overpressed ceramic block, where the supporting profile and the snap profile are formed to the opposing sides of the dental prosthesis. The side of the frame opposite to the supporting profile correspondingly forms the contours of the snap profile. The first ceramic has high hardness than the second ceramic. The first ceramic is aluminum oxide ceramic or zirconium oxide ceramic. The second ceramic is feldspar ceramic. The first ceramic at the side of the frame opposite to the supporting profile directly contacts the second ceramic at the side of the veneer opposite to the snap profile, where the direct contact takes place over the entire side. The veneer and the frame are milled from the ceramic block in a computer-assisted manner. The frame is subtractively worked out from the ceramic block or made of additive from ceramic material. The fabricated frame is post-treated by framing, infiltrating and/or sintering. During overpressing the frame, an insertion axle of the frame is positioned parallel to the side wall of the ceramic block. The edge lengths of the frame block (20) in all three directions is 5-20% larger than the produced dental prosthesis, and lies in the area of 3-5 cmx 1.5-2 cmx 1.5-2 cm. The parameter of the ceramic block corresponds to the parameter of the frame block. The strength of the frame is 0.4-0.5 mm. The strength of the veneer is 0.1-2 mm. The determination of the position of the supporting profile takes place in the ceramic block on the basis of the edges of the frame and/or on the basis of open stumps. The open stumps are scanned, the determined data is inverted and the surface of the frame is calculated on the basis of the inverted stumps. The surface of the veneer is tempered and/or optically changed. Independent claims are included for: (1) a dental prosthesis; and (2) a method for producing body replacement parts.
A novel polypeptide sequence having formula (I) or salt thereof in which A1? is a hydrogen or at least one and no more than two amino acids selected from the group consisting of lysine and arginine, A2? is a tyrosine, phenylalanine or tryptophan residue, A3? is an arginine or lysine residue, A4? is at least one and no more than two amino acids selected from the group consisting of lysine and arginine, and A5? is an -OH or an NH2?, is described. The polypeptide may be used in a pharmaceutical composition as an antimicrobial or antiviral agent, specifically as an anti-HIV agent.
The psychoeducation program is based on the Parent Training for Child ADHD Program developed by Russell Barkley for children with ADHD and other behavioral disorders. It includes: (1) understanding ADHD symptoms, (2) general behavior management principles, (3) positive reinforcement and attending skills, (4) the use of a reward and token system, and (5) child problem-solving skills.